Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer

NCT07103018 is registered in ClinicalTrials.gov with K36 Therapeutics, Inc. as lead sponsor.

NCT NCT07103018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07103018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Dose-Escalation Study of KTX2001 (an NSD2 Inhibitor) Alone and in Combination With Darolutamide for Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
K36 Therapeutics, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 21, 2025
Completion date
September 30, 2028
Enrollment
144 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

mcrpc, mcrpc (metastatic castration-resistant prostate cancer), metastatic castration-resistant prostate cancer, metastatic castration-resistant prostate cancer patients, metastatic castration-resistant prostate cancer, mcrpc